0A4D Stock Chart & Stats
$2.40
-$0.12(-5.00%)
At close: 4:00 PM EDT
$2.40
-$0.12(-5.00%)
Day’s Range― - ―
52-Week Range$0.83 - $3.53
Previous CloseN/A
Volume1.91K
Average Volume (3M)1.49K
Market Cap
$138.23M
Enterprise Value$301.20
Total Cash (Recent Filing)$57.16M
Total Debt (Recent Filing)$584.00K
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Nov 18, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding63,408,080
10 Day Avg. Volume995
30 Day Avg. Volume1,493
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.98
Price to Sales (P/S)0.00
P/FCF Ratio-6.25
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.67Price Target Upside344.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt limits interest and refinancing pressure, preserving financial flexibility for research and development. However, this strength depends on the company managing continued losses without excessive equity issuance.
Targeted Immunology PipelineA focused pipeline addressing severe autoimmune and inflammatory diseases gives Equillium multiple opportunities for clinical or partnering value creation. Success remains uncertain, but asset breadth provides more than one potential development pathway.
Financing And Strategic FlexibilityExpanded authorized share capacity can support future financings, partnerships or strategic transactions needed to advance the pipeline. This does not remove funding risk, but it gives management additional tools to extend operations and pursue development.
Bears Say
No Current RevenueWith no current product revenue, Equillium lacks a recurring operating base to fund research and development. The company remains dependent on future partnerships, milestone receipts or capital markets rather than internally generated commercial cash flow.
Persistent Cash BurnSustained operating and free-cash-flow losses indicate that existing resources are being consumed to maintain the pipeline. Unless spending falls or funding improves, repeated external financing will remain necessary and may constrain development priorities.
Potential Shareholder DilutionThe larger share authorization improves financing capacity but also creates meaningful dilution risk if equity is issued to fund operations. Existing ownership could decline, and future fundraising may become a recurring requirement while revenue remains absent.
Equillium News
0A4D FAQ
What was Equillium Inc’s price range in the past 12 months?
Equillium Inc lowest share price was $0.83 and its highest was $3.53 in the past 12 months.
What is Equillium Inc’s market cap?
Equillium Inc’s market cap is $138.23M.
When is Equillium Inc’s upcoming earnings report date?
Equillium Inc’s upcoming earnings report date is Nov 18, 2026 which is in 82 days.
How were Equillium Inc’s earnings last quarter?
Equillium Inc released its earnings results on Aug 13, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.014.
Is Equillium Inc overvalued?
According to Wall Street analysts Equillium Inc’s price is currently Undervalued.
Does Equillium Inc pay dividends?
Equillium Inc does not currently pay dividends.
What is Equillium Inc’s EPS estimate?
Equillium Inc’s EPS estimate is -0.05.
How many shares outstanding does Equillium Inc have?
Equillium Inc has 63,408,080 shares outstanding.
What happened to Equillium Inc’s price movement after its last earnings report?
Equillium Inc reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 6.573%.
Which hedge fund is a major shareholder of Equillium Inc?
Currently, no hedge funds are holding shares in GB:0A4D
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Equillium Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (344.44% Upside)
$10.67 (344.44% Upside)
Blogger Sentiment
Neutral
GB:0A4D Sentiment 50%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth $723.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
578.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
373.15%
Trailing 12-Months
Company Description
Equillium Inc
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
0A4D Stock 12 Month Forecast
Average Price Target
$10.67
▲(344.44% Upside)
Technical Analysis
NRX Pharmaceuticals
―
Sutro Biopharma
―
MindWalk Holdings
―
Prelude Therapeutics
―
―